A Prospective, Multicenter, Open-label Trial of Zoledronic Acid in Patients with Hormone Refractory Prostate Cancer

다국어 초록 (Multilingual Abstract)

Purpose: The short-term safety and efficacy of zoledronic acid for the treatment of skeletal metastasis was evaluated in patients with hormone-refractory prostate cancer. Patients and Methods: A total of 19 hormone-refractory prostate cancer patients with bone metastases were enrolled. All patients received up to six infusions of zoledronic acid (4mg, given intravenously over 15 minutes, every 3-4 weeks). Safety was assessed by monitoring a`dverse events and serum creatinine levels. Efficacy was assessed by monitoring skeletal-related events, brief pain inventory score, quality of life score, type of pain medication, and analgesic score. Mean age of patients was 67.3 years (46-86 years), mean time from diagnosis of bone metastases was 27.6 months (0-117 months), and mean time from diagnosis of hormone-refractory disease was 7.5 months (0-26 months). Results: There was no clinically significant change in serum creatinine levels. Eleven adverse events (musculoskeletal disorders and systemic disorders) in 8 patients were classed as having a possible relationship to study drug. Fifteen patients completed six courses of zoledronic acid infusion. There were no significant changes in the brief pain inventory composite scores, quality of life questionnaire scores or analgesic score. No new skeletal-related events developed during the treatment period. Conclusion: Zoledronic acid administered in this study as a 15-minute infusion demonstrated an acceptable and well-known safety profile in patients with refractory prostate cancer with bone metastases. However, prospective placebo- controlled clinical trials are required to elucidate the efficacy of zoledronic acid.

참고문헌 (Reference)

1 Cleeland CS, "global use of the Brief Pain Inventory" 129-38,

2 Ryan CW, "Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer" 176 : 972-978, 2006

3 Cheer SM, "Zoledronic acid" 61 : 799-806, 2001

4 Smith MR, "Treatment-related osteoporosis in men with prostate cancer" 12 : 6315S-6319S, 2006

5 Weinfurt KP, "The significance of skeletal- related events for the health-related quality of life of patients with metastatic prostate cancer" 16 : 579-584, 2005

6 Saad F, "The role of bisphosphonates in hormone-refractory prostate cancer" 23 : 14-18, 2005

7 Tong D, "The palliation of symptomatic osseous metastases final results of the Study by the Radiation Therapy Oncology Group" 893-9,

8 Cella DF, "The Functional Assessment of Cancer Therapy scale development and validation of the general measure" 570-9, jclinoncol1993;11

9 Saad F, "Skeletal morbidity in men with prostate cancer: quality-of-life considerations throughout the continuum of care" 46 : 731-740, 2004

10 Guarneri V, "Renal safety and efficacy of i.v. bisphosphonates in patients with skeletal metastases treated for up to 10 Years" 10 : 842-848, 2005

11 Khosla S, "Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men" 86 : 3555-3561, 2001

12 Saad F, "Preventing bone complications in patients with prostate cancer: the emerging role of zoledronic acid" 3 : 25-33, 2004

13 Chen T, "Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases" 42 : 1228-1236, 2002

14 Siddiqui NA, "Osteoporosis in older men: discovering when and how to treat it" 54 : 20-30, 1999

15 Morote J, "Osteoporosis during continuous androgen deprivation: influence of the modality and length of treatment" 44 : 661-665, 2003

16 Coleman RE, "Metastatic bone disease: clinical features, pathophysiology and treatment strategies" 27 : 165-176, 2001

17 Mundy GR, "Metastasis to bone: causes, consequences and therapeutic opportunities" 2 : 584-593, 2002

18 Carroll PR, "Management of disseminated prostate cancer. In: Denis L, Bartsch G, Khoury S, Murai M, Partin A, editors. Prostate Cancer: 3rd International Consultation on Prostate Cancer- Paris" Paris: Health publications 251-284, 2003

19 Smith MR, "Low bone mineral density in hormone-nave men with prostate carcinoma" 91 : 2238-2245, 2001

20 Saad F, "Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer" 96 : 879-882, 2004

21 Ferlay J, "GLOBOCAN 2000: cancer incidence, mortality and prevalence worldwide" Lyon: IARC Press (5) : 2001

22 Smith MR, "Diagnosis and management of treatment- related osteoporosis in men with prostate carcinoma" 97 : 789-795, 2003

23 Ralston SH, "Comparison of three intravenous bisphosphonates in cancer-associated hypercalcaemia" 1180-2, lancet1989;2

24 Ritch P, "Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia" 134-42, jclinoncol1992;10

25 Body JJ, "Clinical research update: zoledronate" 80 : 1699-1701, 1997

26 "Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events" 2006.08.09

27 Migliorati CA, "Bisphosphonate- associated osteonecrosis: a long-term complication of bisphosphonate treatment" 7 : 508-514, 2006

28 Lipton A, "Bisphosphonate treatment of lytic bone metastases" 14 : 241-246, 1999

29 Wei JT, "Androgen deprivation therapy for prostate cancer results in significant loss of bone density" 54 : 607-611, 1999

30 Saad F, "A randomized, placebo- controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma" 94 : 1458-1468, 2002